HealthMore in Health→
EnGene Selloff Puts Fresh Pressure on Bladder Cancer Program
Key Takeaways
- Updated pivotal Phase 2 bladder cancer data triggered a sharp negative market reaction for EnGene.
- The source says investors were alarmed and the therapy’s future prospects came under new pressure.
- The episode underscores how quickly biotech valuations can move on revised clinical data.
DE
DT Editorial Team··via endpoints.news